Passage Bio Q1 net loss $16.7M, cash $104.5M; PBFT02 shows sustained CSF PGRN in 2 patients

Passage BIO, Inc.

2024-Q1 EPS reported -$0.30

Net loss of $16.7M ($0.30/shr) vs $34.3M a year ago; cash $104.5M, runway through Q4 2025.
Dose 1 PBFT02 elevated CSF progranulin (21.7–27.3 ng/mL) at 6 months in 2 FTD-GRN patients.
Completed dosing Cohort 1 (n=5) in upliFT-D trial; 6-month safety/biomarker data due 2H 2024.
Plan to initiate Cohort 2 dosing in 1H 2024; FDA feedback sought for FTD-C9orf72 indication.
Raised $8.7M net under ATM facility in Q1 2024; R&D expenses $11.5M, G&A $6.5M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Passage BIO, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $16.7 million, or $0.30 per basic and diluted share.

Period: first quarter ended March 31, 2024
Net income: Net loss was $16.7 million, or $0.30 per basic and diluted share
Result: reported results

Exact text from the filing

Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2024

View on SEC.gov

1443 earnings releases filed in the last 30 days. Browse all earnings releases →

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-008054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.